RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $465
Truist Securities Reiterates Buy on BeOne Medicines, Raises Price Target to $448
Citizens Maintains Market Outperform on BeOne Medicines, Raises Price Target to $463
Wells Fargo Maintains Overweight on BeOne Medicines, Raises Price Target to $435
Compared to Estimates, BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: A Look at Key Metrics
BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates
Loading...